Galenica Ag · SIX:GALE
Galenica — Investor Presentation (August 2026)
82 slides from Galenica's investor presentation, August 2026
Slide 1: Investor Presentation Galenica Group
Investor Presentation Galenica Group August 2026
Slide 2: Table of contents
Table of contents About Galenica page 03 Market environment page 27 Business performance page 37 Governance page 56 Sustainability page 67 Outlook page 76 August 2026 Investor Presentation Galenica Group 2
Slide 3: About Galenica
| zn! GGalenica About galem : a eee
Slide 4: Galenica in figures
Galenica in figures Net sales1 EBIT adjusted1,2 Galenica Group Galenica Group Leading healthcare provider in Switzerland 381 own pharmacies 26% 35% CHF CHF Employees 4,135.6 234.8 (Headcount) 65% million million > 8,400 74% Dividend yield1 2.6% Products & Care Logistics & IT Products & Care Logistic
Slide 5: Building the leading Swiss healthcare platform
Building the leading Swiss healthcare platform IPO Joint Venture Creation of Amavita uniform Opening of highly brand in Switzerland automated distribution centre in Niederbipp Acquisition Acquisition Umsatz +10.2% 2000 2002 2005 2007 2008 2009 2013 EBIT 2017 +26.4% Organic and acquisition-led expans
Slide 6: Building the leading Swiss healthcare platform
Building the leading Swiss healthcare platform Acquisition Strategic partnership Acquisition Acquisition Acquisition Acquisition Acquisition Participation 2018 2019 2020 2021 2022 2023 2024 2025 Relaunch Joint Venture Joint Venture Acquisition Acquisition Participation Acquisition Strategic partners
Slide 7: Switzerland's leading fully integrated healthcare provider
Switzerland‘s leading fully integrated healthcare provider Largest network of Wide range of home care Leading pharma logistics pharmacies in Switzerland services for patients and provider in the healthcare with over 500 pharmacies, professional service sector. online and offline. providers. Well-kno
Slide 8: There for you every day. #StrongTogether
Values Added value in the network Shaping the future We generate value for customers We are shaping the healthcare and partners Vision of tomorrow Omni-Channel Digital Health Health Services & Products Connecting Healthcare Strategy Strategy Sustainably successful Pioneers in transition We work effi
Slide 9: The Galenica network
@i « bd e Galenica The Galenica network . . Se a Wy > @. 2 e @.86 9 | ) @PADMA e
Slide 10: Our business areas
Our business areas Products & Care1 Logistics & IT 1 Net sales EBIT2 Net sales EBIT2 1,816m CHF 175m CHF 3,333m CHF 62m CHF Pharmacies Products & Services & Diagnostics Wholesale Logistics & IT Omni-Channel Brands Production Services Net sales Net sales Net sales Net sales Net sales Net sales 1,473m
Slide 11: New revenue segmentation
New revenue segmentation 2025 Galenica revised revenue reporting to reflect organizational changes and increase transparency Previously New Products & Care Products & Care Retail (B2C) Pharmacies Omni-Channel Local Pharmacies Products & Brands Pharmacies at Home Professionals (B2B) Services & Produc
Slide 12: Pharmacies Omni-Channel: Three largest pharmacy chains in Switzerland
Pharmacies Omni-Channel Three largest pharmacy chains in Switzerland Key takeaways Largest branded pharmacy network by number of − Largest pharmacy network offers broad product range, pharmacies in Switzerland1 including well-known own brands, as well as health services and tests 209 − Built organic
Slide 13: Pharmacies Omni-Channel: Broad range of product and service offerings
Pharmacies Omni-Channel Broad range of product and service offerings Amavita and Sun Store Service offerings in local pharmacies product offering (selection) in % of sales1 Primary Care Health Checks Prescription medicines of which originals 7% of which generics 19% 39% of which service fees COVID-1
Slide 14: Pharmacies Omni-Channel: Always available where our customers are
Pharmacies Omni-Channel Always available where our customers are Widely spread pharmacy network covers every Demonstrated M&A track record with an average of Region in Switzerland 8 pharmacies acquired and 3 net pharmacies added per year over the last 5 years 2022 2023 2024 2025 H1 26 Pharmacies acq
Slide 15: Strategic JV with Redcare Pharmacy N.V.
Strategic JV with Redcare Pharmacy N.V. The Redcare JV offers compelling long-term upside exposure to the fast-growing Swiss online pharmacy market. Market Share Mail-order pharmacies1 Market leading online and mail-order1 70% pharmacy in Switzerland The business activities of MediService and redcar
Slide 16: Products & Brands: Strong brands for the Swiss Consumer Healthcare Market
Products & Brands Strong brands for the Swiss Consumer Healthcare Market Key takeaways Selected own brands − Leading position1 in the Swiss consumer healthcare market (CHC) − Preferred Consumer Health partner for Swiss Pharmacies & Drugstores − Broad Sales & Training force − Expanding portfolio of o
Slide 17: Products & Brands: Strong brands for the Swiss Consumer Healthcare Market
Products & Brands Strong brands for the Swiss Consumer Healthcare Market Verfora market share in Swiss CHC market1 Market share of main OTC product in 2025 OTC products categories of Verfora1 14.3% market share CHF 245.0 million Vitamins, minerals & Personal care Pain relief nutritional supplements
Slide 18: Products & Brands: Proven M&A track record
Products & Brands Proven M&A track record as key driver for Distribution Cooper Consumer market share growth Acquisition Distribution Boiron® Health® Hedoga Group Acquisition OTC Dr. Wild Beauty Distribution ThermaCare® 10.0% Complementary Medicine Distribution Distribution Allergosan® Vicks and Met
Slide 19: Services & Production: We support healthcare professionals
Services & Production We support healthcare professionals with high quality services Pharmacies • Prepared drugs in blisters ensuring safe medication • Key customers include nursing homes • Lifestage Solutions develops and operates a fully integrated digital trading platform for home care organizati
Slide 20: Services & Production - Homecare: One digital platform
Services & Production - Homecare One digital platform for home care services Artificial nutrition and parenteral therapies Care materials (MiGeL) and billing Overview of services Home doctors Galenica’s comprehensive range of services relieves the burden on specialists and optimises work processes P
Slide 21: Diagnostics: Galenica operates fourth largest lab in Switzerland
Diagnostics Galenica operates fourth largest lab in Switzerland 70% of all diagnoses are based on lab analyses Established player with deep market knowledge Significant previous investments in innovation, infrastructure & digitalisation Strong foundation for growth with Galenica August 2026 Investor
Slide 22: Wholesale: Leader in wholesale distribution
Wholesale Leader in wholesale distribution Key takeaways Wholesale market share1 Wholesale market share1 % physician channel % pharmacy channel − Wide product range with around 100,000 products in pharma, non-pharma, practice & laboratory equipment and medical devices, whereof around 50% in stock 25
Slide 23: Wholesale: Leader in wholesale distribution
Wholesale Leader in wholesale distribution Wholesale distribution with four distribution centers Customers by channel Pharmacies ~ 1,300 Drugstore ~ 300 Medical practices > 5,600 Hospitals/Nursing homes > 570 August 2026 Investor Presentation Galenica Group 23
Slide 24: Logistics & IT Services: Leader in pre-wholesale distribution
Logistics & IT Services Leader in pre-wholesale distribution Key takeaways Pre-wholesale market share1 Warehouse capacity − Third-party logistics provider for the pharmaceutical industry No. 3 9% 37,900 m2 (pre-wholesaling) including No. 2 38% additional services (labeling, repacking, clinical trial
Slide 25: Logistics & IT Services: Patient safety, convenience and efficiency
Logistics & IT Services Our approach towards more patient safety, convenience and efficiency Diagnosis Clinical Decision Support (CDS.CE) (medication and vaccination) Prescription Medication Master Data E-Prescription Anamnesis Patients on-/offline Therapy e-Mediplan August 2026 Investor Presentatio
Slide 26: Strategic partnerships
Strategic partnerships Galenica as preferred partner in Swiss Healthcare Strategic partnerships Product Health Digital eHealth Pharmacies Logistics distribution Insurances Platforms Solutions - Basic insurance models - Verfora is preferred distribution partner for products in - JV with Planzer - JV
Slide 27: Market environment
Market environment
Slide 28: Swiss healthcare market: resilient and stable growth
Swiss healthcare market Proven track record of resilient and stable growth Development of Swiss healthcare retail sector1 in billion CHF (based on ex-manufacturer price) 2025-28 CAGR 4%2 8 2014-25 CAGR 4.2% 7 6 6.6 6.9 6.1 6.4 5 5.6 5.8 5.3 4 4.6 4.9 4.2 4.4 4.4 4.5 3.9 4.1 3 2 1 0 2014 2015 2016 20
Slide 29: Swiss pharmaceutical market June 2026
Swiss pharmaceutical market June 2026 Total market growth CHF 4,074.7 million (+3.7%) Hospitals 99.1 million packs (-0.6%) CHF 962.4 million (+0.2%) 7.7 million packs (+1.2%) 23.6% Drugstores 0.7% 43.6% Local Pharmacies CHF 29.0 million (-2.9%) CHF 1,777.6 million (+5.4%) 2.7 million packs (-4.3%) 6
Slide 30: Swiss pharmaceutical market
Swiss pharmaceutical market in million CHF 760 740 720 700 680 660 640 620 600 580 560 540 520 500 Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez 2024 2025 2026 Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospital
Slide 31: Galenica as key driver of generic substitution
Swiss pharmaceutical market Galenica as key driver of generic substitution in Switzerland Drugs reimbursable by health insurance in Swiss pharmacy channel June 2026 YTD (by packs) Substitution rate Pharmacies Galenica Group3 Patent protected products 2.7 million, +9.1% 79.6% Originals/Reference prod
Slide 32: Generic penetration largely stable in H1 2026
Swiss pharmacy market by drug category Generic penetration largely stable in H1 2026 Swiss Pharmacy Channel Swiss Pharmacy Channel (Split by value) (Split by volume) 19.2% 20.3% 20.0% 19.7% Products with expired patent 45.8% 45.6% 45.0% 44.1% protection without generics / out of market / others2 46.
Slide 33: Consumer healthcare market June 2026
Consumer healthcare market June 2026 Total market 2.8% CHF 1,310.0 million +0.2% 12.7% OTC 0.0% Personal care -1.1% 19.4% Patient care Non-medication +2.7% segment 65.1% +0.5% Nutrition +1.2% Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA – Consumer Heal
Slide 34: Swiss healthcare market: regulatory environment
Swiss healthcare market: regulatory environment Topic/Initiative Current status Reduction in drug prices − Standard process, FOPH verifies drug prices in a three-year cycle OTC products:1 − Federal Council presented a proposal, consultation starting most probably in 2026 online trade − Implementatio
Slide 35: Constant pressure on drug prices
Swiss healthcare market: regulatory environment Constant pressure on drug prices Annual savings per channel due to price cuts of SL products at public and ex-factory price in million CHF Pharmacies Physicians Hospitals 200 180 160 31 140 30 120 47 100 13 12 41 80 34 11 27 32 24 11 21 60 20 19 20 13
Slide 36: Concept of distribution margin
Swiss healthcare market: regulatory environment Concept of distribution margin (valid since 1 July 2024) FOPH defines price and margin – Margin covers wholesale and retail 70 Old model (until 30 Jun 2024) Current model (since 1 Jul 2024) Old model Current model 60 Ex factory + price- + surcharge Ex
Slide 37: Business performance
Business performance Our success story
Slide 38: Performance overview Galenica Group
Performance overview Galenica Group History of resilient growth and margin improvement 2014 – 2022 including MediService 2023-2025 w/o MediService (incl. discontinued operations) (continuing operations) CAGRs CAGRs Galenica net sales 4.5% Galenica net sales 5.1% Galenica EBIT 1 7.0% Galenica EBIT3,
Slide 39: Strong performance development in both segments
Performance overview Galenica Group Strong performance development in both segments Products & Care Logistics & IT 5.4% 5.4% 4.0% 2,030 3,333 1,908 3,077 3,180 7 1,8164 1,683 1,6364 1,700 2,831 2,933 Net sales (CHFm) 4 1,437 1,479 1,525 1,621 2,362 2,372 2,441 2,625 1,335 1,393 2,171 2,245 2,329 201
Slide 40: Strong sales growth supported by acquisition of Labor Team
Galenica Group Strong sales growth supported by acquisition of Labor Team Net sales (in million CHF) +7.1% 2,136 +4.2% 1,995 1,618 1,685 +11.5% 967 H1 2025 867 H1 2026 Galenica Group Products & Care Logistics & IT Growth w/o Labor Team +4.0% +4.3% +4.2% August 2026 Investor Presentation Galenica Gro
Slide 41: Strong sales growth in both segments
Galenica Group Strong sales growth in both segments Net sales (in million CHF) H1 2025 H1 2026 change Pharmacies Omni-Channel 713.0 756.9 +6.2% Products & Brands 101.1 91.2 -9.8% Services & Production 57.9 63.4 +9.4% Diagnostics 0.0 62.2 Products & Care 867.3 967.2 +11.5% Wholesale 1’579.6 1’647.3 +
Slide 42: Pharmacies Omni-Channel: Growth driven by prescription medicines
Pharmacies Omni-Channel Growth driven by prescription medicines and acquisitions Net sales (in million CHF) Expansion impact1 of +1.9% due to 1,473 acquisition of majority stake in puravita, portfolio of local pharmacies expanded by 3 locations +6.2% 713 757 Generics substitution rate remains with 7
Slide 43: Products & Brands: Seasonal effects burden sales
Products & Brands Seasonal effects burden sales development Net sales (in million CHF) 194 -9.8% 36 International 101 Swiss market: 91 Swiss market − Growth of CH market sales1 -2.6% 21 15 -27.8% 158 − Market share1 of 10.5% 80 76 -5.1% 2025 H1 2025 H1 2026 1) Product sales to end customers of Verfo
Slide 44: Services & Production: Strong sales growth in homecare
Services & Production Strong sales growth in homecare business Net sales (in million CHF) 120 +9.4% Consistent, strong growth with services for homecare 63 58 organizations and nursing homes 2025 H1 2025 H1 2026 August 2026 Investor Presentation Galenica Group 44
Slide 45: Wholesale: Further market share gains
Wholesale Further market share gains in pharmacies segments Net sales (in million CHF) 3,255 934 Physicians +4.3% Pharmacies 1,580 1,647 Others 461 465 +1.0% 2,136 1’027 1’092 +6.3% 185 92 90 -2.0% 2025 H1 2025 H1 2026 August 2026 Investor Presentation Galenica Group 45
Slide 46: Logistics & IT Services: Stable development
Logistics & IT Services Stable development with Prewholesale and IT services Net sales (in million CHF) 80 -0.8% 39 39 2025 H1 2025 H1 2026 August 2026 Investor Presentation Galenica Group 46
Slide 47: Strong EBIT growth excluding prior-year one-off effects
Strong EBIT growth excluding prior-year one-off effects EBIT adjusted1) (in million CHF) ROS (in %) 117.7 +12.6% 109.9 104.5 25.3 +2.0% 30.2 -5.4 1.5% 1.9% 24.8 1.5% Logistics & IT Products & Care 93.3 +15.2% 81.0 81.0 9.6% 9.3% 9.3% H1 2025 3 one-off 2 H1 2025 H1 2026 items w/o one-off 1 without ef
Slide 48: Gross margin & Personnel cost
Gross margin & Personnel cost Overall improvement of gross margin Grossmargin: Grossmargin in % net sales H1 2025 H1 2026 H1/H1 VJ − Pharmacies margins are under pressure Galenica Gruppe 27.6% 28.7% 1.0% from a higher Rx mix, while Diagnostics Products & Care 46.3% 47.5% 1.2% margins are accretive L
Slide 49: Adjusted Net Profit & Loss Statement
Adjusted Net Profit & Loss Statement1 in million CHF H1 2025 H1 2026 in % Net sales 1’995 2’136 +7.1% D&A : Increase due to go-live of Other income 9 7 -19.9% Wholesale ERP system in Ecublens Cost of goods -1’445 -1’524 +5.5% Financial Results: Decline compared Personnel costs -302 -331 +9.5% to the
Slide 50: Balance sheet: Debt coverage shift
Balance sheet Debt coverage shift driven by seasonal WC build in million CHF 1,509 1,465 1,443 Equity adjusted1 837 675 Net debt adjusted1 533 2025 H1 2025 H1 2026 Debt coverage 2.3x 1.9x 2.7x adjusted2 1 Detail of the adjustments in the Half year report 2026, see chapter “Alternative performance me
Slide 51: Condensed balance sheet
Condensed balance sheet in million CHF Dec 2025 Jun 2026 Change Cash and cash equivalents 116 40 -76 Trade receivables and current Trade and other receivables 527 630 +103 liabilities: Increase, mainly reflecting seasonal working capital Inventories 385 396 +11 effects and ERP migration Other assets
Slide 52: Cash Flow Statement
Cash Flow Statement in million CHF H1 2025 H1 2026 Cash flow from operating activities before working 125.8 126.7 Operating cash flow: Higher capital changes adjusted1 working capital driven by seasonal Working capital changes -43.5 -93.8 effects, delayed invoicing and ERP 1 82.4 32.9 migration prep
Slide 53: Investments deferred into H2 2026
Investments deferred into H2 2026 in million CHF 61.1 29.4 Investments in intangible assets 31.3 27.6 Investments in 12.5 15.9 tangible assets 31.8 15.1 15.4 2025 H1 2025 H1 2026 in % of net sales 1.5% 1.4% 1.5% August 2026 53 Investor Presentation Galenica Group
Slide 54: Dividend Proposal
Dividend Proposal Board of Directors increased dividend by 8.7% 69.9% 68.2% 62.8% 66.5% 64.7% 59.7% 2.50 2.30 2.20 2.20 2.10 1.80 2020 2021 2022 2023 2024 2025 1 Dividend per share Payout ratio 1 Dividend per share in relation to adjusted earnings per share at reporting date August 2026 Investor Pre
Slide 55: Share information: Key figures
Share information Key figures in CHF Dec 2025 Jun 2026 Share price at reporting date 97.70 84.30 Market capitalisation at reporting date in million CHF 4,867.8 4,198.6 Earnings per share 01/01 – 30/06 from continuing operations1 1.77 1.34 Earnings per share adjusted 01/01 – 30/06 from continuing ope
Slide 56: Governance
(2) 3 Cc 4g (e) O © ¥ A Ba | \ ea | 1 amame | Bi meee | > E [CTo)
Slide 57: Shareholder structure
Shareholder structure Proportion of shareholders by country (30 Dec 2025) in % Major shareholders (31 Dec 2025) 0.4% − Shareholders over 3%: Switzerland Shareholders Number of shares Shares in % UBS Fund Management (Switzerland) AG, 5,487,581 11.0 UK Switzerland 38.2% Alecta Pensionsförsäkring, Swed
Slide 58: Overview of our governance structure and instruments
Overview of our governance structure and instruments General Meeting External advisory and inspection bodies / auditors Board of Directors Audit and Remuneration Governance, Nomination and Sustainability Risk Committee (ARC) Committee (RC) Committee (GNSC) Corporate Executive Committee Extended EC P
Slide 59: Board of Directors
Board of Directors Dr. Markus − Elected since 2019 Judith Meier − Elected since 2022 R. Neuhaus − Master of law and doctorate in law from the University − Executive Master of Health Service Administration of Zurich − Member of the Board of Directors of the Cantonal Chair − Vice-Chair of the Board of
Slide 60: Board of Directors: Committees and competencies
Board of Directors1 Committees and competencies ARC (Audit and Risk Committee) Members: Jörg Zulauf Budget / medium-term planning (Chairman), Bertrand Jungo, Judith Meier, Nadine Risk management Balkanyi-Nordmann Compliance / internal audits Acquisitions / investments Non-Financial Reporting RC (Rem
Slide 61: Board of Directors: Competencies and diversity
Board of Directors1 Competencies and diversity Competencies Neuhaus Bruderer Jungo Meier Peters Zulauf Nadine Markus Pascale Bertrand Judith Solange Jörg Balkanyi- Nordmann Industry x x x x x x Experience Digitalisation x x x x Regulations/ x x x x x Politics Leadership/ x x x x x Big Corp. Finance/
Slide 62: Board of Directors: Competencies and diversity
Board of Directors1 Competencies and diversity Age of BoD members Gender of BoD members (December 2025) (December 2025) 14% 46 - 50: 29% 51 - 55: 43% male 56 - 60: 57% 43% 29% female 57% 61 - 65: 14% 14% 66 - 70: 1 The Board of Directors as of 31.12.2025 August 2026 Investor Presentation Galenica Gr
Slide 63: Our organisation
Our organisation August 2026 Investor Presentation Galenica Group 63
Slide 64: Our Leadership Team
Our Leadership Team Executive Committee Extended Executive Committee Marc Werner Thomas Szuran Julian Fiessinger Lukas Ackermann Arianne Hasler Iris Müller Jürg Pauli Group CEO Chief Products & Home Group CFO Chief IT & Digital Chief People & Culture Chief Corporate Chief Sustainability, Public Care
Slide 65: Remuneration
Remuneration Responsibility for the remuneration process Remuneration Board of Level of authority CEO Annual General Meeting Committee Directors consultative vote on the Remuneration policy proposes approves Remuneration report Performance objectives for short-term proposes approves bonus and long-t
Slide 66: Remuneration
Remuneration Remuneration components STI LTI − The remuneration components of the Corporate Executive Committee (EC) 25% ESG 50% consists of a fixed compensation, benefits and a variable compensation. average − The variable remuneration consists of a short-term incentive (STI) and a long- GEP term i
Slide 67: Sustainability
* alenica ‘Sustainability:
Slide 68: Sustainability at Galenica: Overview
Sustainability at Galenica Overview Sustainability principles Company value Employees Resource efficiency We increase the value of the We oblige our employees to act We use resources sparingly and company in the long term by responsibly and ensure they efficiently and reduce negative having a sustai
Slide 69: Relevance matrix of material topics
Sustainability at Galenica Relevance matrix of material topics August 2026 Investor Presentation Galenica Group 69
Slide 70: Our sustainability goals
Sustainability at Galenica Our sustainability goals Corporate governance Patients Ethical and legal business activities Increase patient and health safety Protect patient data and IT systems Ensure the availability of medicinal products Employees Environment Promote employee motivation and developme
Slide 71: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Measurement Goal Status year parameter 2023 2024 2025 We raise awareness of compliance issues among our Every Number of employees at least six times a = 4 7 9 year measures year, tailored to the respective target group. We raise awareness of
Slide 72: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Goal Status year Measurement parameter 2023 2024 2025 We will increase the use of Clinical Decision Support Checks (CDS.CE) to Number of CDS.CE checks 2030 278 million 369 million 553 million 500 million by 2025 and 1 billion by (Clinical De
Slide 73: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Goal Status year Measurement parameter 2023 2024 2025 Employee survey "Opinio": The participation rate should be above 75 Every Motivation rate 76 / 100 76 / 100 78 / 100 = per cent. The motivation rate between year Participation rate 72% 76
Slide 74: Our sustainability goals
Sustainability at Galenica Our sustainability goals Target Status Goal year Measurement parameter 2023 2024 2025 Galenica commits to reduce absolute Scope 1 and 2 GHG tCO2 reduction to base year 2035 n/a -21% -27% emissions 65% by 2035 from a (marked-based) 2023 base year. Galenica also commits that
Slide 75: ESG Ratings
ESG Ratings Rating-Agentur Actual Rating Comment ESG Risk − Ranking number 20 among 614 Healthcare companies (Rating of 12.0) NEGL LOW MED HIGH SEVERE − Good scores in Business ethics, Data privacy and security, Governance and Carbon emissions in own operations (Aug 2025) Absolute Rating D- D D+ C-
Slide 76: Outlook
Outlook
Slide 77: Market development expectations
Market development expectations1 Based on the demographic trends and innovation with many new, high-priced medications, Galenica expects continued strong growth of +/- 5% in the Swiss pharmaceutical market2 in the next years. The strongest growth is expected in the hospital channel. For pharmacies a
Slide 78: Guidance 2026
Guidance 2026 Galenica Group net sales +5% to +7% EBIT adjusted1 +6% to +8% (corresponds +9% to +11% without PY one-off items). The costs associated with the intended closure of Bichsel’s production division will mainly be incurred in the first half of 2026 and are not reflected in the adjusted EBIT
Slide 79: Updated mid-term Guidance
Updated mid-term Guidance Galenica expects net sales to grow by 3% to 5% in the next years. Segment Logistics&IT: until 2027, Galenica expects a stable development of its return on sales (ROS)1 due to an intense final phase of the ERP project with a planned migration in H2 2026 and subsequent winddo
Slide 80: Reasons to invest in Galenica
Reasons to invest in Galenica Unique combination of defensive resilience and significant growth Defensive resilience History of growth Strategic focus Proven strategy to leverage Stable and attractive Swiss Significant operational market leadership positions to healthcare market with advantages from
Slide 81: Galenica Group – Contact information
Galenica Group – Contact information Investor Relations Julian Fiessinger Tel: +41 58 852 85 31 CFO investors@galenica.com Florian Urech Tel: +41 58 852 83 42 Head of Investor Relations investors@galenica.com and Corporate Finance August 2026 Investor Presentation Galenica Group 81
Slide 82: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n